End-of-day quote
Other stock markets
|
||
- USD | - |
Jun. 05 | Relay Therapeutics to Collaborate with Pfizer to Evaluate Breast Cancer Treatment | DJ |
Jun. 05 | Relay Therapeutics to Collaborate With Pfizer to Evaluate Metastatic Breast Cancer Treatment | MT |
Financials (USD)
Sales 2024 * | 60.51B | Sales 2025 * | 62.72B | Capitalization | 167B |
---|---|---|---|---|---|
Net income 2024 * | 6.88B | Net income 2025 * | 10.51B | EV / Sales 2024 * | 3.74 x |
Net Debt 2024 * | 59.14B | Net Debt 2025 * | 54.22B | EV / Sales 2025 * | 3.53 x |
P/E ratio 2024 * |
22.4
x | P/E ratio 2025 * |
15.1
x | Employees | - |
Yield 2024 * |
5.67% | Yield 2025 * |
5.78% | Free-Float | 59.05% |
Latest transcript on Pfizer Inc
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 22-05-01 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 20-03-31 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 17-02-22 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 13-09-26 |
1st Jan change | Capi. | |
---|---|---|
+42.69% | 750B | |
+34.11% | 606B | |
-6.87% | 356B | |
+18.74% | 326B | |
+6.76% | 286B | |
+18.08% | 246B | |
-3.44% | 213B | |
+11.35% | 213B | |
+6.72% | 165B |